Poor progression-free survival

Author: ozez

August undefined, 2024

WebSep 27, 2024 · It is associated with rapid disease progression and a shorter progression free survival. ... which results in the loss of TP53, is the most important prognostic marker in CLL and is associated with poor outcomes, rapid disease progression and is historically associated with resistance to standard fludarabine-based chemoimmunotherapy. WebMethods Forty-three nasopharyngeal carcinoma patients less than 19 years old were recruited between April 2010 and April 2016. All patients were treated with IMRT (total dose 61.2-76 Gy) combined with cisplatin based chemotherapy. The Kaplan-Meier test was used to calculate overall survival (OS) and progression-free survival (PFS).

Liver Metastasis Is Associated with Poor Progression-Free …

WebFeb 27, 2012 · The last few years have seen an increase in the number of randomized controlled trials (RCTs) of new agents in metastatic solid tumors using progression-free survival (PFS) as the primary end point. Some trials showing improvement in PFS, without a corresponding increase in overall survival (OS), have led to approval of new drugs and/or … WebNational Center for Biotechnology Information ipek hanimin ciftligi

PIK3CA gene mutation associated with poor prognosis of lung …

WebMay 20, 2024 · Progression-free survival (PFS) and overall survival (OS) were determined by Kaplan–Meier method. The median OS and PFS after first-line treatment were 9.7 and 4.0 years, respectively. Webprogression-free survival: , PFS In cancer care, the time during which a patient shows no signs or symptoms of the growth or the spreading of a tumor. WebProgression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". In … open windows mail windows 10

Objective response rate and progression-free survival as surrogate …

A nomogram model based on pre-treatment and post-treatment …

WebJun 1, 2024 · Disease-free survival (DFS) is a number that tells the chances of staying free of a disease or cancer after a particular treatment. 1 It is the percentage of individuals in the treatment group who are likely to be free of the signs and symptoms of a disease after a specified duration of time. Disease-free survival rates are an indication of how ... WebNov 17, 2016 · SNAP23 is hyper-expressed in OC tumor tissues compared to normal tissues, and increased expression of SNAP23 is associated with a poor progression free survival (HR = 1.24, 95% CI = 1.07–1.44, p = 0.0042). SNAP23 knock down increases cell apoptosis and inhibits cell proliferation, migration and invasion of OC cells. ipek international gmbh sulzbergWebMar 28, 2024 · Among patients with tumors harboring mESR1, elacestrant was associated with a 45% reduction in the risk of progression or death compared with standard therapy.In this subgroup, the median PFS was 3.79 months with elacestrant and 1.87 months with standard endocrine therapy (HR, 0.54; p =.0005). Elacestrant was associated with a higher … ipek international gmbh leipzig

"WebDec 6, 2024 · Survival of patients with breast cancer has increased in recent years due to the improvement of systemic treatment options. Nevertheless, the occurrence of brain metastases is associated with a poor prognosis. Moreover, most drugs do not penetrate the central nervous system because of the blood–brain barrier. Thus, confirmed intracranial … " - Poor progression-free survival

Poor progression-free survival

Progression-free survival and overall survival: (A) Kaplan-Meier ...

WebApr 6, 2024 · miR-25 overexpression in CD138+ plasma cells is associated with poor overall and progression-free survival. Kaplan–Meier survival curves for A overall survival (OS) and B progression-free survival (PFS) of the screening cohort, and for C OS of the MMRF CoMMpass validation cohort, according to CD138+ miR-25 expression. WebApr 7, 2024 · A Progression-free survival and B overall survival in DLBCL patients with low, medium, or high normalized levels of surface TREM2 on M-MDSCs. Normalized MFI changes of surface TREM2 on M-MDSCs being grouped into < 2%, 2–44%, and > 44%; cut-off values for normalized MFI changes of surface TREM2 determined by ROC analysis and AUC.

Did you know?

WebJan 5, 2024 · The authors used a meta-analytic approach to ascertain the correlation between OS and second progression-free survival (PFS-2) and compared that with first progression-free survival (PFS-1) as well as ORR in contemporary randomized controlled trials of advanced solid malignancies that used PFS-2 as a prespecified end point. 4 PFS … WebApr 20, 2024 · Approximately 31% of patients diagnosed with multiple myeloma (MM) have pre-existing hypertension, but its effects on patient survival have not been investigated. …

WebFeb 9, 2015 · Purpose To conduct analyses exploring trial-level and patient-level associations between overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) in advanced non–small-cell lung cancer (NSCLC) trials. Methods We identified 14 trials (N = 12,567) submitted to US Food and Drug Administration since 2003 … WebNov 12, 2024 · Progression-free survival (PFS) was defined according to revised National Cancer Institute criteria. Imaging evaluation was performed on each patient at TT. TMTV, evaluated on 18 FDG-PET, and tumor bulk, measured on CT, were analyzed at TT, after the last bridging treatment, if any, and before starting the lymphodepletion therapy.

WebDisease-free survival. This is the percentage of people who have no signs of their cancer during a period of time after treatment. It is sometimes called recurrence-free survival. … WebWe investigated the relationship between progression-free survival (PFS) and patient characteristics. Results: In both univariate and multivariate analysis, performance status …

WebFeb 27, 2012 · The last few years have seen an increase in the number of randomized controlled trials (RCTs) of new agents in metastatic solid tumors using progression-free …

WebThe patients were divided into high and low sIL-2R groups based on the median of sIL-2R levels at pretreatment. Progression-free survival (PFS) and overall survival (OS) of patients in the high and low sIL-2R groups were compared. The Kaplan–Meier curves of PFS and OS were evaluated using the log-rank test. open windows not showing on screenWebFeb 17, 2024 · Progression-free survival rate. This is the number of people who have been treated for cancer and either have no signs of cancer recurrence or who have cancer that … open windows media app ipek university turkeyWebMay 8, 2024 · Of note, 10% of the patients had PS 2 at baseline and those patients who developed treatment-related rash (79%) had significantly better progression-free survival (PFS) and OS, with a median OS of 14.3 months versus 4.2 months. Considering the limited data in poor PS patients from clinical trials, real-life data become useful in decision-making. ipek tenolcay agencyWebDec 1, 2024 · The 1-year overall survival and progression-free survival rates were 78.0% and 50.2%, respectively. Furthermore, we identified extramedullary disease, light chain multiple myeloma, and certain high-risk cytogenetic factors as important independent predictors of a poor prognosis in those receiving anti-BCMA CAR T-cell therapy. open windows powershell admin windows 10WebJan 1, 2024 · Kaplan-Meier analysis for progression-free survival according to CRP in (A) whole study population, (B) melanoma patients, (C) NSCLC patients and (D) GU cancer … open windows powershell greyed outWebProgression-free survival as a potential surrogate for overall survival in metastatic breast cancer Catherine Beauchemin,1 Dan Cooper,2 Marie-Ève Lapierre,1 Louise Yelle,3 Jean ... open windows on mac